Indication: 

For the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK.

For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received chemotherapy.